3 ms·

I wonder why she didn't try Ketamine first. It's barely mentioned in the article.

jokoon 5y ago
> The maintenance therapy with ketamine (from twice a week to once in two weeks) appears to be a promising option, although the evidence to firmly recommend it is insufficient https://en.wikipedia.org/wiki/Ketamine#Depression https://en.wikipedia.org/wiki/Ketamine#Depression > The approval of esketamine for TRD by the FDA was controversial due to limited and mixed evidence of efficacy and safety. > In January 2020, esketamine was rejected by the National Health Service (NHS) of Great Britain.[41] The NHS questioned the benefits of the medication for depression and claimed that it was too expensive. https://en.wikipedia.org/wiki/Esketamine#Depression https://en.wikipedia.org/wiki/Esketamine#Depression It's too early, and it's for treatment resistant depression. So yeah, unless you're a doctor/neurologist and know the protocol for validating drugs, it's not really worth listening to the pseudo science advocated by drug users who also encourage taking psilocybin/LSD/MDMA as a silver bullet, and constantly talk about pharma conspiracies. "Listen to the professionals" is a better advice.
- Tenoke 5y ago
  I don't know about Wikipedia's editors but decent meta-analyses were already showing solid results in 2014[0] and this meta-analysis of 24 RCTs this year also shows decent results. The NHS reasoning is that it's too expensive, not ineffective and even that seems odd to me as it's produced pretty cheaply to use for variety of purposes. I'd guess the expense is due to the patents of esketamine used to approve it for depression while being able to profit, but that seems to be the less effective type at any rate. 0. https://link.springer.com/article/10.1007/s00213-014-3664-5 https://link.springer.com/article/10.1007/s00213-014-3664-5 1. https://www.sciencedirect.com/science/article/abs/pii/S016503272032766X https://www.sciencedirect.com/science/article/abs/pii/S01650...

> The maintenance therapy with ketamine (from twice a week to once in two weeks) appears to be a promising option, although the evidence to firmly recommend it is insufficient https://en.wikipedia.org/wiki/Ketamine#Depression https://en.wikipedia.org/wiki/Ketamine#Depression > The approval of esketamine for TRD by the FDA was controversial due to limited and mixed evidence of efficacy and safety. > In January 2020, esketamine was rejected by the National Health Service (NHS) of Great Britain.[41] The NHS questioned the benefits of the medication for depression and claimed that it was too expensive. https://en.wikipedia.org/wiki/Esketamine#Depression https://en.wikipedia.org/wiki/Esketamine#Depression It's too early, and it's for treatment resistant depression. So yeah, unless you're a doctor/neurologist and know the protocol for validating drugs, it's not really worth listening to the pseudo science advocated by drug users who also encourage taking psilocybin/LSD/MDMA as a silver bullet, and constantly talk about pharma conspiracies. "Listen to the professionals" is a better advice.

Tenoke 5y ago
I don't know about Wikipedia's editors but decent meta-analyses were already showing solid results in 2014[0] and this meta-analysis of 24 RCTs this year also shows decent results. The NHS reasoning is that it's too expensive, not ineffective and even that seems odd to me as it's produced pretty cheaply to use for variety of purposes. I'd guess the expense is due to the patents of esketamine used to approve it for depression while being able to profit, but that seems to be the less effective type at any rate. 0. https://link.springer.com/article/10.1007/s00213-014-3664-5 https://link.springer.com/article/10.1007/s00213-014-3664-5 1. https://www.sciencedirect.com/science/article/abs/pii/S016503272032766X https://www.sciencedirect.com/science/article/abs/pii/S01650...